Clinical Trial Update: Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating low-dose decitabine for refractory aplastic anemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Refractory Aplastic Anemia | Phase 2 | Status: TERMINATED